Simris Group
Simris Group is a Swedish biologics company focused on identifying and commercialising natural bioactive compounds from microalgae and cyanobacteria. Its work spans discovery, extraction and development of compounds for use in biopharmaceuticals, dietary supplements and cosmetics, with shares listed on Nasdaq First North Growth Market in Sweden.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueNatural compounds and payload candidates developed for antibody-drug conjugates and oncology applications.
Omega-3 and other supplement products and ingredients sold through distributors and direct channels.
Bioactive natural ingredients intended for use in cosmetic formulations.
Preclinical studies, screening and development work around proprietary cyanobacterial compounds.
Customers
Simris Group serves pharmaceutical and biotech counterparties interested in novel payloads for targeted cancer therapies, especially ADC developers and research partners. It also addresses consumer-facing and ingredient markets through dietary supplement and cosmetic applications, where buyers seek natural, differentiated bioactive inputs. The customer base therefore spans early-stage biopharma collaborators, ingredient buyers and end-market distributors.
Buy or evaluate ADC payload candidates and preclinical data for oncology programs.
Support in vitro and in vivo studies of proprietary compounds and payload platforms.
Purchase omega-3 supplement products for resale through retail and online channels.
Source natural bioactive ingredients for formulation into cosmetic products.
Strategy
Simris Group is concentrating on proprietary cyanobacteria-derived payloads for antibody-drug conjugates and related oncology applications. The company is also evaluating the future of its production assets and has reduced emphasis on lower-value consumer supplement activity, aiming to focus resources on higher-value scientific programs and partnership opportunities.
Proprietary payload science is the core value driver and differentiator.
External validation and collaboration are needed to convert science into commercial value.
The production asset base must align with capital availability and strategic focus.
Geography
Simris Group is headquartered in Sweden and is listed on Nasdaq First North Growth Market in Stockholm. Its reported activity is international in nature, with European research partners and prospective counterparties mentioned in the reports, and with the Hammenhög production asset in Sweden forming part of the operational base. The business is exposed to cross-border collaboration, regulatory requirements and supply-chain execution across Europe and beyond.
Risks
Simris Group faces the typical risks of an early-stage biotech company: scientific uncertainty, long development timelines and dependence on external funding. Its legacy supplement and production activities also expose it to execution risk, while any partnership or asset-sale process can be delayed or fail to close on acceptable terms.
- External funding dependenceImpact: CriticalLikelihood: High
The company is in a start-up phase and relies on new capital to continue operations and growth plans.
Exposure: Corporate funding and working capital
- Scientific and development riskImpact: HighLikelihood: Medium
ADC payload programs depend on preclinical results, technical validation and eventual partner interest.
Exposure: Microcystin payload platform
- Asset divestment execution riskImpact: Medium
The Hammenhög sale process may take time, fail, or close below expectations.
Exposure: Production facility and related assets
- Commercialization risk in supplementsImpact: Medium
Consumer supplement sales have been de-emphasized and may not provide meaningful scale.
Exposure: Omega-3 supplement channel
Accounting
Judgemental itemsBiotech programs often involve judgment on whether costs are expensed or capitalized, affecting earnings and asset values.
Impact: Reported operating result and intangible assets
The Hammenhög facility and related production assets may need impairment testing or sale accounting.
Impact: Balance sheet carrying values and gain/loss on disposal
Loans with conversion rights can affect classification, interest expense and equity dilution.
Impact: Liabilities, finance costs and share count
Board-linked loans and consulting services require transparent disclosure under Swedish reporting rules.
Impact: Governance and note transparency
Similar listed companies
Publicly listed companies with a comparable business focus.
SynAct Pharma
SYNACT · Health Care
SynAct Pharma AB is a clinical stage biotechnology company based in Lund, Sweden, specializing in the resolution of inflammation through the selective activation of the melanocortin system.
BioGaia
BIOG-B · Health Care
BioGaia AB is a Swedish company specializing in the development, manufacturing, and marketing of probiotic products aimed at enhancing gut, oral, and immune health.
Cyanotech Corp
CYAN · Medicinal Chemicals & Botanical Products
Cyanotech Corp is a U.S.-based producer of microalgae-derived nutritional ingredients and finished supplements, built around Hawaiian Spirulina Pacifica and BioAstin Hawaiian Astaxanthin.
Rapid Micro Biosystems, Inc
RPID · Laboratory Analytical Instruments
Rapid Micro Biosystems is a U.S.-based life sciences technology company that develops the Growth Direct platform for automated microbial quality control in pharmaceutical manufacturing.
Nordicus Partners Corp
NORD · Services-Management Consulting Services
Nordicus Partners Corp is a U.S.-listed business accelerator and holding company focused on Nordic life sciences ventures.
Kalaris Therapeutics, Inc.
KLRS · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026